Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis
NCT03237260 · University of Pennsylvania · PHASE4 · withdrawn · last registry update 2019-07-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No patient accrual” | – | Registry record, University of Pennsylvania |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-06-23Results posted on the registry: Takeda, Vedolizumab SC 108 mg + Placebo (NCT02611817)
- 2020-05-14Also stopped (withdrawn): Marc Schwartz, Vedolizumab + placebo (NCT02834754)
- 2020-04-17Results posted on the registry: Dana-Farber Cancer Institute, Natalizumab + Methylprednisolone (NCT02176031)
- 2020-03-04Results posted on the registry: Takeda, Vedolizumab (NCT02559713)
- 2020-01-23Results posted on the registry: Takeda, Vedolizumab 300 mg IV + Placebo IV (NCT02611830)
- 2019-12-16Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Entyvio (Vedolizumab) (NCT02788175)
- 2019-12-09Results posted on the registry: Takeda, Vedolizumab + Vedolizumab placebo (NCT02038920)
- 2019-11-18Results posted on the registry: Takeda, Vedolizumab SC (NCT03948581)
- 2019-10-10Results posted on the registry: Takeda, Vedolizumab + Adalimumab placebo (NCT02497469)
- 2019-10-04Phase 3 first posted: Polpharma Biologics S.A., Intravenous (IV) infusions (NCT04115488)
- 2019-09-27Also stopped (terminated): Biogen, Daclizumab (NCT02881567)
- 2019-09-25Results posted on the registry: Takeda, Vedolizumab + Placebo (NCT02630966)
- 2019-09-24Results posted on the registry: Biogen, Daclizumab (NCT02881567)
- 2019-09-23Results posted on the registry: Takeda, Vedolizumab SC (NCT03961308)
- 2019-09-13Results posted on the registry: University of Wisconsin, Madison, Standard dose Influenza vaccine (SDIV) + High dose influenza vaccine (HDIV) (NCT02461758)
- 2019-09-06Results posted on the registry: Takeda, Vedolizumab (NCT03329209)
- 2019-08-29Also stopped (terminated): ANRS, Emerging Infectious Diseases, GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine + GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab (NCT02972450)
- 2019-08-26Results posted on the registry: Takeda, Vedolizumab (NCT02728895)
- 2019-08-22Phase 3 first posted: Centre Hospitalier Universitaire de Saint Etienne, Valganciclovir (NCT04064697)
- 2019-08-19Results posted on the registry: Takeda, Vedolizumab SC (NCT03961295)
- 2019-08-12Results posted on the registry: Takeda, Vedolizumab SC (NCT03949621)
- 2019-08-07Phase 3 first posted: National Institute of Allergy and Infectious Diseases (NIAID), Best Available Therapy (BAT) (NCT04047628)
- 2019-07-05Results posted on the registry: AstraZeneca, MEDI7183 low dose + MEDI7183 medium dose (NCT01959165)
- 2019-06-27Results posted on the registry: Amgen, Abrilumab + Placebo (NCT01696396)
- 2019-06-27Results posted on the registry: Amgen, Abrilumab + Placebo (NCT01694485)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision